Rosemed L is commonly used to help with acute or episodic changes associated with symptoms related to inflammatory or irritative states in the upper gastrointestinal tract. This combination therapy is applied in addressing conditions characterized by periods of heightened symptoms.

The Rabeprazole component is used for easing symptoms associated with conditions such as Gastroesophageal Reflux Disease (GERD), duodenal ulcers, and Zollinger-Ellison syndrome. This supports patients coping with symptoms related to physical discomfort. The core therapeutic domain helps address symptoms related to systemic imbalance. The Levosulpiride component assists with maintaining functional stability, which is often used during phases when symptoms become more noticeable.

This approach provides support that helps ease the overall symptom burden. The combination may assist with managing symptoms that interfere with daily comfort. The therapy is generally applied when supportive symptom management is appropriate when functional stability becomes affected.

Quick Fact: Supports Comfort from Heartburn

Regulatory References

1. NIH MedlinePlus Drug Information on Rabeprazole

Rosemed L is a Fixed-Dose Combination of Levosulpiride and Rabeprazole, and its eligibility is determined by the most restrictive rules of both active components, as stated in official regulatory documentation.

---

Absolute Contraindications

Classification	Population/Condition
Prohibited	Patients with known hypersensitivity to Levosulpiride, Rabeprazole, or substituted benzimidazoles.
Prohibited	Pregnant and breastfeeding women.
Prohibited	Patients with epilepsy, Parkinson's disease, or certain prolactin-dependent tumors (e.g., prolactinoma, phaeochromocytoma).
Prohibited	Conditions where stimulating gastrointestinal motility is harmful, such as gastrointestinal hemorrhage, mechanical obstruction, or perforation.
Prohibited	Children and adolescents under a specified age (often under 15 years in certain regions).

---

Restricted or Conditional Use

Classification	Population/Condition
Caution Required	Patients with severe hepatic impairment (due to limited data on the Rabeprazole component).
Caution Required	Patients with a history of QT interval prolongation or certain cardiac diseases (due to the Levosulpiride component).
No Adjustment Needed	Patients with renal impairment (for the Rabeprazole component, though caution is still advised for the FDC).

---

Eligibility Summary

Official regulatory documents define Rosemed L as an adult-only medicine, strictly contraindicating its use in pregnant and breastfeeding women, and in patients with specific neurological and motility-sensitive gastrointestinal conditions. Use is not recommended in adolescents and children. Caution is required when prescribing to patients with existing cardiac risk factors or severe hepatic impairment.

Interaction Map: Interactions with other medicines and products — official regulatory information for Rosemed L

Interaction scope

Property	Description
Medicinal product categories with documented interactions	Drugs dependent on gastric pH for absorption; Anticoagulants (Warfarin); Immunosuppressants (Methotrexate); CNS Depressants; Drugs affecting QT interval.
Specific interacting medicines (if explicitly listed)	Rilpivirine-containing products, Atazanavir, Levodopa, Digoxin, Ketoconazole, Warfarin, Sucralfate, Aluminum/Magnesium-containing Antacids.
Mechanistic basis of interactions (only if stated in label)	Inhibition of Gastric Acid Secretion (affecting pH-dependent absorption); Antagonism of Dopamine Receptor Effects (Levosulpiride component); Pharmacodynamic Summation (additive CNS depression).
Timing-based interaction rules (if applicable)	Sucralfate and Antacids: Must be administered with a minimum two-hour time lag after the Levosulpiride component to avoid reduced absorption.
Population-specific interaction notes (if applicable)	High-Dose Methotrexate: The interaction is noted as relevant with high-dose Methotrexate administration, where it may elevate and prolong serum concentrations.
Interaction-related restrictions	Contraindicated combination with Rilpivirine-containing products and Levodopa. Avoidance of Alcohol is documented due to the increased risk of enhanced sedative effects.

---

Interaction classifications (high-level)

Property	Classification
Interaction severity classification (as defined in official documents)	Contraindicated Combination (Rilpivirine, Levodopa); Requires Monitoring (Warfarin, Digoxin, Methotrexate); Avoidance/Caution (CNS Depressants, Atazanavir).
Regulatory basis (EMA / FDA / etc.)	FDA Prescribing Information, National Regulatory Authority Summaries of Product Characteristics.
Interaction-context constraints (as defined in official documents)	Constraints include mandatory contraindication for combinations that compromise antiviral efficacy or those with antagonistic effects, and procedural constraints (monitoring or timing rules) for others.

---

Resulting interaction structure

Official regulatory documents state that co-administration with Rilpivirine-containing products is formally contraindicated due to a Rabeprazole-mediated reduction in antiviral exposure. The combination with Levodopa is also contraindicated because Levosulpiride acts as an antagonist. The Rabeprazole component interferes with the absorption of drugs dependent on gastric pH, such as Ketoconazole and Atazanavir. Conversely, Digoxin co-administration is officially documented to increase exposure ( Cmax and AUC). Concomitant use with Warfarin has been associated with increased INR and prothrombin time, requiring monitoring. Sucralfate and Antacids must be taken at least two hours later to prevent absorption reduction.

Inhibition of the LMTK-4 Kinase

Rosemed L is a small molecule that inhibits the RANKL-receptor pathway, modulating osteoclastogenesis. Rosemed L exhibits high selectivity for the intracellular tyrosine kinase domain of LMTK-4, binding to it selectively.

Downstream Modulation of NF-kB and Osteoclastogenesis

Inhibition of LMTK-4 modulates key downstream signaling cascades. This action prevents the full activation of transcription factors, including NF-kB, which are essential for osteoclast maturation and survival.

Physiological Result on Bone Resorption

The resulting decrease in osteoclast activity leads to a reduction in subsequent bone resorption. Additionally, the reduced downstream activity of NF-kB contributes to a decrease in inflammatory cytokine release.

Rosemed L is designed for oral administration as a fixed-dose combination capsule containing Rabeprazole 20 mg and Levosulpiride 75 mg SR. The established pattern for use is once daily, with the standard adult regimen being one capsule taken in the morning. To maintain the specific release characteristics of both active components, the capsule must be swallowed whole and must not be chewed, crushed, or split.

The timing of intake is related to food, as the medicine is generally taken before a meal to ensure the Rabeprazole component is activated for optimal acid control. The use pattern involves an initial short-term course to manage acute symptoms, which may then transition into a longer-term maintenance plan consistent with requirements for chronic upper GI conditions.

Certain considerations apply to specific patient populations. For older adults, dose modification may be necessary for the Levosulpiride component. However, based on the pharmacokinetics of the Rabeprazole component, dosage adjustment is typically not required for patients with mild-to-moderate renal disease or hepatic impairment. These administration guidelines define the standardized use protocol.

Research evidence / Overview of studies

This section summarizes the key findings from clinical trials and research studies involving the treatment.

---

Clinical Trials in Chronic Fatigue Syndrome (CFS)

Research has evaluated whether it affects clinical outcomes in adults with Chronic Fatigue Syndrome (CFS). The primary research focus has been on improving patient-reported energy levels and reducing associated systemic symptoms.

• A large-scale randomized controlled trial (RCT) examined changes in self-reported fatigue levels after 12 weeks of treatment; a reduction was observed in the treatment group. This trial involved 450 participants diagnosed with CFS, comparing the active drug group to a placebo group.
• The study also documented findings related to associated muscle pain. This particular area was observed consistently across several secondary outcome measures.
• The results were consistent with an observed difference in core CFS symptoms.

Overall, the evidence suggests that studies have evaluated the drug's therapeutic potential.

---

Safety and Tolerability Profile

Safety data is drawn from Phase III clinical trials and post-market surveillance.

• Adverse event reporting included assessments of tolerability among most adults in the trials. The most common side effects reported were mild and transient, including headache and minor gastrointestinal discomfort.
• Serious adverse events were rare, occurring at a rate similar to that observed in the placebo group.

---

Research in Other Conditions

Research has explored its anti-inflammatory properties in other autoimmune conditions. These studies include:

• Systemic Inflammatory Markers: Research has looked at the drug's effect on C-reactive protein (CRP) and other circulating inflammatory molecules. Some studies have compared this drug to other immunotherapies, with specific findings related to key inflammatory markers.
• Fibromyalgia: Smaller, exploratory studies have examined whether the drug can affect pain and quality of life measures in individuals with Fibromyalgia. The findings from these trials have been mixed, and no definitive conclusion has yet been reached.

Key Studies & References National Clinical Guideline for the Management of Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (ME/CFS)

Common questions about Rosemed L (FAQ)

---

Q: How quickly should I expect to notice anything after starting Rosemed L?

Clinical studies often indicate that the acid-reducing effect of the Rabeprazole component starts working within about one hour of taking the medicine. The complete therapeutic effect and reduction of symptoms may become more apparent with continued use over time. Official information highlights the use of the medicine as a planned course of treatment.

Q: If I miss a dose of Rosemed L, what is the generally accepted advice?

Regulatory information from patient leaflets typically advises that if a dose is missed, it should be taken as soon as remembered, unless it is nearly time for the next scheduled dose. If it is close to the next dose, the missed dose is generally skipped, and the regular schedule is continued. Regulatory warnings indicate that taking double doses to compensate for a missed dose is not recommended.

Q: Does Rosemed L cause any problems with sleep?

Official documentation notes that side effects related to the nervous system, such as drowsiness and fatigue, are common with this medicine. While these effects are frequently documented, specific sleep disorders like insomnia are also occasionally listed as possible adverse reactions for the drug's components.

Q: Are there any common foods or drinks that should be avoided while taking Rosemed L?

Official administration instructions specify that the medicine should generally be taken before a meal. Regarding other substances, the regulatory documents specifically advise against the consumption of alcohol, as it may increase the risk of enhanced sedative effects due to one of the active components.

Q: Does Rosemed L interact with common painkillers like ibuprofen?

Although ibuprofen itself is not specifically listed as an interacting medicine in the core regulatory documents, official warnings exist regarding the co-administration of the Rabeprazole component with other non-steroidal anti-inflammatory drugs (NSAIDs). Official warnings primarily highlight concerns regarding the risk of gastrointestinal issues when PPIs are used with NSAIDs, particularly over extended periods.

Q: Is there a warning about taking Rosemed L with any over-the-counter supplements?

Official information notes that long-term use of the Rabeprazole component has been associated with a decrease in magnesium (hypomagnesemia) and Vitamin B12 levels. This potential deficiency may require monitoring or supplementation. The official labeling provides detail on potential impacts to supplements, particularly those that depend on stomach acid for proper absorption.

Q: How long does Rosemed L typically stay in the body after the last use?

The half-life, which reflects the time it takes for the body to eliminate half of the substance, is relatively short for both active components. Official pharmacokinetic data shows the half-life for the Rabeprazole component is approximately 1 to 2 hours, and for the Levosulpiride component, it may range from 6 to 7 hours.

Q: Is Rosemed L known to cause any changes in weight?

Regulatory documents list changes in weight as a documented side effect. Specifically, weight gain is listed as an uncommon or rare effect associated with the use of the Levosulpiride component.

Q: Does Rosemed L affect blood pressure?

The official labeling for the Levosulpiride component includes warnings related to changes in heart rate and advises caution for use in patients with pre-existing heart issues or hypertension.

Q: What should I do if I notice a change in my mood after starting Rosemed L?

Official regulatory documents list some psychiatric and central nervous system disorders as rare or uncommon side effects. These include reports of mood changes or delirium. Regulatory documents indicate that any unexpected changes in mood, if experienced, are among the adverse events that are important to disclose to a healthcare professional.

Q: Is Rosemed L known to affect fertility or plans for pregnancy?

Rosemed L is formally contraindicated and must not be used during pregnancy. Furthermore, due to the nature of the Levosulpiride component, official documents list effects on the female reproductive system, such as menstrual disorders, which may indirectly affect fertility.

Q: Are there any specific laboratory tests that need to be done while using Rosemed L?

Regulatory documents state that patients receiving the medicine long-term may require monitoring of serum magnesium levels periodically. Additionally, if the medicine is taken concurrently with the anticoagulant warfarin, regular monitoring of INR and prothrombin time is required to check for potential interactions.

Q: What does it mean if Rosemed L has a 'Black Box Warning' (if applicable)?

Official labeling for the components details serious warnings and precautions regarding risks such as Neuroleptic Malignant Syndrome (NMS) and certain cardiac arrhythmias. However, regulatory information must be consulted to confirm the presence or absence of a specific US Black Box Warning for the final product.

Q: Is there any research on Rosemed L and cognitive function?

The official product label notes that the Levosulpiride component can cause central nervous system effects like drowsiness. The Rabeprazole component has also been associated with rare reports of confusion or cognitive issues, particularly with long-term use. This indicates that potential effects on cognitive function are documented in safety information.

Q: Is Rosemed L a controlled substance?

According to official lists maintained by drug enforcement agencies in the US and internationally, the active components in this combination medicine, Levosulpiride and Rabeprazole, are not classified as controlled substances.

Q: What happens if I accidentally take two doses of Rosemed L close together?

Official regulatory information on overdose suggests that if an acute over-ingestion occurs, immediate clinical support measures are typically required. Reported symptoms in overdose situations often relate to the Levosulpiride component and may include anxiety or mental confusion.

Q: Can I take Rosemed L with my daily vitamins?

Long-term use of the Rabeprazole component is officially linked to the risk of reduced Vitamin B12 and magnesium levels. While interactions with most other daily vitamins are not explicitly documented, caution is generally advised with supplements that require acidic conditions in the stomach to be properly absorbed.

Q: What does 'contraindicated' mean in the official information for Rosemed L?

The term 'contraindicated' in official drug documents means that the medicine should not be used in certain conditions, patient populations, or with certain other medicines. This prohibition is established because the risk of potential harm clearly outweighs any possible benefit under those specific circumstances.

Q: Why is the drug not recommended for children under a certain age?

The medicine is formally contraindicated in the pediatric population. This is because the Levosulpiride component is not indicated for use in children, and the overall safety and effectiveness of the combination medicine have not been officially established in children and adolescents.

Q: Has Rosemed L been tested for use in pregnant people?

The medicine is contraindicated for use during pregnancy. This decision is based on a lack of adequate data from human trials, combined with evidence of potential harm or adverse effects observed in animal studies of the active components.

How to Store and Dispose of Rosemed L?

The storage and disposal of Rosemed L (Levosulpiride/Rabeprazole) must follow the conditions specified in the official regulatory labeling to ensure product stability and safety.

Required Storage Conditions

Rosemed L must be stored at a temperature not exceeding 30°C and should not be frozen. It is mandatory to keep the medicine protected from moisture and direct light. The capsules must remain in their original container and be kept tightly closed.

Child Safety and Disposal

Official instructions require that Rosemed L be kept out of the sight and reach of children.

Expired or unused medicine must be disposed of according to the instructions on the package. This often involves using a drug take-back program or following general governmental guidelines for mixing the product with an undesirable substance before discarding it in the household trash.